ATE273682T1 - Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung - Google Patents

Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung

Info

Publication number
ATE273682T1
ATE273682T1 AT99973935T AT99973935T ATE273682T1 AT E273682 T1 ATE273682 T1 AT E273682T1 AT 99973935 T AT99973935 T AT 99973935T AT 99973935 T AT99973935 T AT 99973935T AT E273682 T1 ATE273682 T1 AT E273682T1
Authority
AT
Austria
Prior art keywords
formulations containing
topical formulations
skin penetrating
penetrating agents
containing skin
Prior art date
Application number
AT99973935T
Other languages
English (en)
Inventor
Rajaram Vaidyanathan
Phuong M Vo
George N Manning
Geoffrey Allan
Atef A Helmy
Original Assignee
Durham Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durham Pharmaceuticals Ltd filed Critical Durham Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE273682T1 publication Critical patent/ATE273682T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
AT99973935T 1999-06-25 1999-09-28 Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung ATE273682T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14075699P 1999-06-25 1999-06-25
PCT/US1999/022313 WO2001000139A1 (en) 1999-06-25 1999-09-28 Topical formulations comprising skin penetration agents and the use thereof

Publications (1)

Publication Number Publication Date
ATE273682T1 true ATE273682T1 (de) 2004-09-15

Family

ID=22492675

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99973935T ATE273682T1 (de) 1999-06-25 1999-09-28 Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung

Country Status (15)

Country Link
US (1) US6271219B2 (de)
EP (1) EP1194109B1 (de)
JP (1) JP2003506462A (de)
KR (1) KR100623534B1 (de)
AT (1) ATE273682T1 (de)
AU (1) AU769079B2 (de)
BR (1) BR9917389B1 (de)
CA (1) CA2376850C (de)
DE (1) DE69919597T2 (de)
DK (1) DK1194109T3 (de)
ES (1) ES2224755T3 (de)
MX (1) MXPA01013460A (de)
NZ (1) NZ516765A (de)
PT (1) PT1194109E (de)
WO (1) WO2001000139A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057616A1 (en) * 2004-11-29 2006-06-01 Ambria Dermatology Ab A composition comprising at least 3 different diols
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
NZ539106A (en) 2002-10-10 2007-02-23 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US7964751B2 (en) 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
KR100987121B1 (ko) * 2010-08-12 2010-10-12 연세대학교 산학협력단 창문닦기로봇
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
AR096459A1 (es) * 2013-06-03 2015-12-30 Tolmar Inc Composiciones de corticosteroides y método de fabricación
CN104161721A (zh) * 2014-07-14 2014-11-26 湖北博康医药科技有限公司 一种用于治疗皮肤病的蛇王药剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE843140A (fr) 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4886783A (en) 1986-01-31 1989-12-12 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
JPH0676328B2 (ja) * 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
DK0437225T3 (da) * 1990-01-10 1994-06-27 Hoffmann La Roche Topiske præparater
JP3207212B2 (ja) * 1991-03-01 2001-09-10 久光製薬株式会社 吸収促進剤およびこれを含有する外用剤
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
JPH06219947A (ja) * 1993-01-26 1994-08-09 Kinki Univ 経皮投与製剤
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5952000A (en) * 1996-10-30 1999-09-14 Theratech, Inc. Fatty acid esters of lactic acid salts as permeation enhancers

Also Published As

Publication number Publication date
DE69919597T2 (de) 2005-07-14
WO2001000139A1 (en) 2001-01-04
DK1194109T3 (da) 2004-10-25
EP1194109A1 (de) 2002-04-10
JP2003506462A (ja) 2003-02-18
AU6060799A (en) 2001-01-31
BR9917389B1 (pt) 2013-04-24
MXPA01013460A (es) 2003-09-04
CA2376850A1 (en) 2001-01-04
US6271219B2 (en) 2001-08-07
CA2376850C (en) 2009-11-17
BR9917389A (pt) 2002-03-05
US20010001790A1 (en) 2001-05-24
NZ516765A (en) 2003-04-29
PT1194109E (pt) 2004-12-31
EP1194109B1 (de) 2004-08-18
DE69919597D1 (de) 2004-09-23
EP1194109A4 (de) 2003-01-15
AU769079B2 (en) 2004-01-15
ES2224755T3 (es) 2005-03-01
KR20020038595A (ko) 2002-05-23
KR100623534B1 (ko) 2006-09-18

Similar Documents

Publication Publication Date Title
CA1146070A (en) Topical triethylenetetramine-containing pharmaceutical compositions and methods of use
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
CA1307207C (en) Steroid lotion
PE20001032A1 (es) Composiciones y metodos para tratar enfermedades pulmonares
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
ATE200733T1 (de) Pharmazeutische zubereitungen, die fluoxetin enthalten
ATE125445T1 (de) Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
ATE214931T1 (de) Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
BR0204596A (pt) Composição tópica, e, métodos para melhorar a aparência estética da pele, para intensificar a eficácia terapêutica de uma composição tópica para a pele, unha, lábios e/ou cabelo e para intensificar a produção de um constituinte de célula de planta predeterminada
SE9900961D0 (sv) Novel compounds
ATE273682T1 (de) Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
ATE358474T1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
SE9602644D0 (sv) New use
GEP20043231B (en) Resorcinol Composition
NZ336600A (en) Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation
JP2016501236A (ja) 炎症性皮膚状態の予防および治療のための方法
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação
IT1257884B (it) Formulazioni farmaceutiche per il trattamento di malattie periferiche vascolari a base di vincamina o di un suo sale farmaceuticamente accettabile.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1194109

Country of ref document: EP

EEIH Change in the person of patent owner